ClinicalTrials.gg
CompletedNCT01579383Updated Apr 26, 2013

Safety Tolerability and Pharmacokinetics of ALD403

A Phase 1 interventional study of ALD403 and ALD403 in Migraine Disorders, sponsored by Alder Biopharmaceuticals, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-04-26.

Sponsored by Alder Biopharmaceuticals, Inc. (part of H. Lundbeck A/S) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.

Enrollment
17th of 21
104 · median 193
Started
2012
the only one that year
Phase 1
3 of 21
none open now
Registered
1st of 21
by date
Lead sponsor
6 of 21
Alder Biopharmaceuticals, Inc.

Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 17th largest by enrollment, is the only one that started in 2012, is one of 3 in phase 1, and was the 1st registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About eptinezumab

eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing eptinezumab in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD403, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.

03

Conditions studied

  • Migraine Disorders

Browse trials for

Keywords

  • Migraine Disorders
  • Phase 1
  • ALD403
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria Part A:

  • Healthy males and females between the ages of 18 and 65 (inclusive).
  • Normal renal function as calculated by the equation at screening.
  • (BMI) between 18.0 and 30.0 kg/m2, and a total body weight of 50 to 100kg inclusive.
  • No disease or abnormal laboratory values as determined by medical history, physical examination, , and laboratory evaluations

Exclusion Criteria Part A:

  • History of febrile illness within 5 days prior to the first dose
  • Any clinically significant laboratory findings
  • Any clinically significant physical exam abnormalities
  • Hospitalization for any reason within 30 days of the screening visit.
  • History of or positive (HIV) screen result
  • History of positive surface antigen (HBsAg), and/or positive antibody (HCV) at screening.
  • History of within five years prior to screening.
  • History of leukemia, myeloproliferative disorder or lymphoproliferative disorder
  • History of rubber, latex allergy or allergy to medical adhesives
  • Positive urine, drug or alcohol screen result
  • Current smokers
  • Previous treatment or clinical trial with a monoclonal antibody.
  • Participation in any clinical research study evaluating another drug or therapy within 30 days or at least 5 half-lives

Inclusion Criteria Part B:

  • Healthy females between the ages of 18 and 65 (inclusive).
  • Male and female migraine patients with clinically diagnosed migraine not attributed to another cause with or without aura based on International Headache Society criteria.
  • Migraine patients must have a history of migraine with or without aura for more than 1 year with 1-8 moderate or severe migraine attacks per month in the 2 months prior to starting in the study.
  • Normal renal function as defined by Cockcroft- Gault equation at screening.
  • Body Mass Index (BMI) between 18.0 and 30.0 kg/m2, and a total body weight of 50 to 100kg inclusive.
  • No clinically significant disease or abnormal laboratory values as determined by medical history, physical examination, electrocardiogram, and laboratory evaluations conducted at the screening visit or at the time of admission

Exclusion Criteria Part B:

  • For migraine patients: patient is not able to refrain from use of their usual triptan therapy (if applicable) from 48 hours (Day -2) prior to dosing on Day 1 until the morning of discharge (Day 3).
  • Migraine patients who experience migraine with prolonged aura, familiar hemiplegic migraine, migrainous infarction or basilar migraine
  • For migraine patients: patient has more than 8 headache-days per month or has taken medication for acute headache on more than 8 days a month in the past 3 months
  • For migraine patients: patient was greater than 50 years old at the age of migraine onset
  • History of febrile illness within 5 days prior to the first dose
  • Any clinically significant laboratory findings
  • Any clinically significant physical exam abnormalities
  • Previous treatment or clinical trial with a monoclonal antibody.
  • Hospitalization for any reason within 30 days of the screening visit.
  • History of or positive human immunodeficiency virus (HIV) screen result
  • History of positive Hepatitis B surface antigen (HBsAg), and/or positive Hepatitis C antibody (HCV
  • History of malignancy within five years prior to screening.
  • History of leukemia, myeloproliferative disorder or lymphoproliferative disorder
  • Positive urine drug or alcohol screen result
  • Current smokers.
  • Known to sumatriptan
  • Participation in any clinical research study evaluating another investigational drug or therapy within 30 days or at least 5 half-lives
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Part A, Cohorts A - H

    ALD403/Placebo

    Biological: ALD403

  • Experimental
    Part A, Cohort I

    ALD403/Placebo

    Biological: ALD403

  • Experimental
    Part B

    ALD403/Placebo/Sumatriptan

    Biological: ALD403 · Biological: Sumatriptan

Interventions

  • BiologicalALD403

    Single Dose IV infusion on Day 1

  • BiologicalALD403

    Single Dose subcutaneous injection on Day 1

  • BiologicalSumatriptan

    Single Dose subcutaneous injection on Day 1

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of ALD403: laboratory variables, ECG and adverse events

    * Physical Examination * Vital signs * 12-lead ECG (electrocardiogram) * Clinical laboratory tests (hematology, chemistry) * Number of participants with Adverse Events

    Time frame: 12 weeks

Secondary outcomes

  1. Evaluation of Pharmacokinetics of ALD403

    * Cmax - maximum plasma concentration * Tmax - Time to achieve maximum plasma concentration * AUC - Area under the plasma concentration-time curve * T1/2 - Elimination half-life * Vz - Volume of distribution * CL - Clearance * Bioavailability

    Time frame: 12 weeks

  2. Evaluation of pharmacodynamics of ALD403

    * Blood perfusion rates * Plasma levels of unbound ALD403 * Immunogenicity

    Time frame: 12 weeks

07

Study locations

1 site
  • Centre for Clinical Studies, Nucleus Network
    Melbourne, Victoria 3004, Australia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Dec 2012 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2012
First posted
Apr 18, 2012
Start
Apr 2012
Primary completionActual
Dec 2012
CompletionActual
Apr 2013
Last update
Apr 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01579383
Responsible party
Sponsor
First posted
Apr 18, 2012
Start date
Apr 2012
Primary completion
Dec 2012
Completion
Apr 2013
Last update
Apr 26, 2013

Study contacts

Peter Hodsman, MD
principal investigator · Nucleus Network

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eptinezumab

Start the discussion